This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate an investigational medication in subjects with type 2 diabetes mellitus who are not adequately controlled by metformin alone.
The medication belongs to a class of diabetic medication called SGLT2 inhibitors. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine. The calories that are lost in the excreted glucose in the urine may help with weight reduction that could benefit many subjects with Type 2 diabetes mellitus (T2DM).
About 350 subjects in the United States and Japan will participate in this study. Your participation in this study will last up to 29 weeks and will require up to 8 visits to the study center.
For your time and travel to the study site for your participation, you will be paid up to a total of $800 if you complete all visits. If you do not complete the study, for any reason, you will be paid for the visits you do complete.